SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Open Lending Corporation (NASDAQ: LPRO) securities between February 24, 2022 and March 31, 2025, both dates inclusive (the “Class Period”), have until this upcoming Monday, June 30, 2025 to seek appointment as lead plaintiff of the Open Lending class action lawsuit. Captioned Bradley v. Open Lending Corporation, No. 25-cv-00650 (W.D. Tex.), the Open Lending class action lawsuit charges Ope ...

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a revision of full-year revenue projections [3]. - The company attributed its disappointing results to "recent launch dynamics," including slow treatment timelines and higher-than-expected patient drop-off rates [6]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to its portrayal of authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5]. - The lawsuit claims that the company misrepresented the operational efficiency of ATCs, which were reportedly experiencing delays and inefficiencies [5]. Group 4: Market Reaction - Following the disclosure of underwhelming first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 to $1.75 per share within a day [7].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2] - Following the announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Rocket and certain of its o ...

Core Viewpoint - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the safety and clinical trial protocol of its RP-A501 treatment, particularly concerning Serious Adverse Events (SAEs) that occurred during the trial [1][2][4]. Group 1: Allegations and Misrepresentation - The lawsuit claims that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the risks associated with the clinical trial, including the death of participants [2][3]. - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to inflated stock prices based on misleading information [3][4]. Group 2: Impact of the Clinical Hold - On May 27, 2025, Rocket announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient experienced a Serious Adverse Event resulting in death, which was not disclosed to investors prior to the amendment [4]. - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% [5]. Group 3: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP is representing the investors in this case, emphasizing their long-standing expertise in securities litigation and commitment to protecting investor rights [5][6].

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Digimarc Corporation ("Digimarc Corporation" or the "Company") (NASDAQ: DMRC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Digimarc Corporation investors who were adversely affected by alleged securities fraud between May 3, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/digim ...

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Civitas Resources, Inc. ("Civitas Resources" or the "Company") (NYSE: CIVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Civitas Resources investors who were adversely affected by alleged securities fraud between February 27, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/civi ...

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/f ...

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Red Cat Holdings, Inc. ("Red Cat Holdings, Inc." or the "Company") (NASDAQ: RCAT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Red Cat Holdings, Inc. investors who were adversely affected by alleged securities fraud between March 18, 2022 and January 15, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra ...

Core Viewpoint - A class action securities lawsuit has been filed against Rocket Companies, Inc. for alleged securities fraud affecting investors between March 29, 2021, and April 1, 2021 [1] Group 1: Allegations of Fraud - The lawsuit claims that Rocket Companies made false statements regarding its gain on sale margins, which were contracting at the highest rate in two years due to increased competition and unfavorable market conditions [2] - It is alleged that Rocket was involved in a price war with competitors, further compressing margins in its Partner Network operating segment [2] - The complaint indicates that Rocket's gain on sale margins were expected to decline by at least 140 basis points in the first half of 2021, returning to levels not seen since Q1 2019 [2] - The favorable market conditions that previously allowed Rocket to achieve high gain on sale margins had disappeared, leading to a significant drop below recent historical averages [2] - Positive statements made by the defendants about the company's operations and prospects were claimed to be materially misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until July 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]